Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod

Rajiv I. Nijhawan, Jeremy M. Hugh, Achiamah Osei-Tutu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patients, and only a limited number of anecdotal treatment options. Systemic retinoids, either independently or in combination with other treatment modalities, have been used with limited success, demonstrating transient clinical response and recurrence of lesions after cessation of therapy. We report a case of an HIV-positive patient with acquired EDV who achieved sustained clinical resolution even after discontinuation of oral acitretin by applying topical imiquimod to prevent recurrence of his lesions.

Original languageEnglish (US)
Pages (from-to)348-349
Number of pages2
JournalJournal of Drugs in Dermatology
Volume12
Issue number3
StatePublished - Mar 2013

Fingerprint

imiquimod
Epidermodysplasia Verruciformis
Acitretin
Immunocompromised Host
HIV
Recurrence
Retinoids
Therapeutics
Randomized Controlled Trials

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{cbd49d1e45e344c1a62de84dbe38af9e,
title = "Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod",
abstract = "Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patients, and only a limited number of anecdotal treatment options. Systemic retinoids, either independently or in combination with other treatment modalities, have been used with limited success, demonstrating transient clinical response and recurrence of lesions after cessation of therapy. We report a case of an HIV-positive patient with acquired EDV who achieved sustained clinical resolution even after discontinuation of oral acitretin by applying topical imiquimod to prevent recurrence of his lesions.",
author = "Nijhawan, {Rajiv I.} and Hugh, {Jeremy M.} and Achiamah Osei-Tutu",
year = "2013",
month = "3",
language = "English (US)",
volume = "12",
pages = "348--349",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "3",

}

TY - JOUR

T1 - Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod

AU - Nijhawan, Rajiv I.

AU - Hugh, Jeremy M.

AU - Osei-Tutu, Achiamah

PY - 2013/3

Y1 - 2013/3

N2 - Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patients, and only a limited number of anecdotal treatment options. Systemic retinoids, either independently or in combination with other treatment modalities, have been used with limited success, demonstrating transient clinical response and recurrence of lesions after cessation of therapy. We report a case of an HIV-positive patient with acquired EDV who achieved sustained clinical resolution even after discontinuation of oral acitretin by applying topical imiquimod to prevent recurrence of his lesions.

AB - Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patients, and only a limited number of anecdotal treatment options. Systemic retinoids, either independently or in combination with other treatment modalities, have been used with limited success, demonstrating transient clinical response and recurrence of lesions after cessation of therapy. We report a case of an HIV-positive patient with acquired EDV who achieved sustained clinical resolution even after discontinuation of oral acitretin by applying topical imiquimod to prevent recurrence of his lesions.

UR - http://www.scopus.com/inward/record.url?scp=84874594314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874594314&partnerID=8YFLogxK

M3 - Article

C2 - 23545921

AN - SCOPUS:84874594314

VL - 12

SP - 348

EP - 349

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 3

ER -